Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Caelyx

- PMLiVE

Roche’s Avastin gets new EU nod in ovarian cancer

Wins new approval for hard-to-treat platinum-resistant recurrent form of disease

- PMLiVE

NICE set to block post-Velcade use of Revlimid

Watchdog's new draft guidance does not recommend Celgene blood cancer drug

National Institute for Health and Care Excellence NICE logo

Lilly’s Efient and Sucampo’s Amitiza win NICE backing

Blood clot and constipation drugs recommended for NHS use

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

National Institute for Health and Care Excellence NICE logo

NICE confirms wider statin use

Reduces threshold for risk of heart disease

Biogen Idec building

NICE green light for Biogen’s oral MS drug

Overturns previous negative guidance for Tecfidera

- PMLiVE

NICE backs Lundbeck’s alcohol dependence drug Selincro

Alcoholics in England to have access to once-daily drug

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

- PMLiVE

NICE backs Janssen’s once-daily diabetes drug

Invokana is the tenth treatment recommended in England and Wales to lower blood sugar levels

National Institute for Health and Care Excellence NICE logo

NICE backs constipation treatment

Sucampo’s Amitiza set for NHS use in England and Wales

UK flag

NICE guidelines on atrial fibrillation discourage aspirin use

Health watchdog encourages greater NHS use of new anticoagulant drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links